NCT03664544View on ClinicalTrials.gov

PK Study in Subjects With Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 6, 2018

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions
Severe Hepatic ImpairmentHealthy
Interventions
DRUG

MCI-186

30 mg MCI-186 will be administered intravenously over 60 minutes.

Trial Locations (3)

Unknown

Investigational Centre, Prague

Investigational Centre, Miskolc

Investigational Centre, Bratislava

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY